Evaluation of the effect of CHF6795 on the pharmacokinetics of midazolam, repaglinide and rosuvastatin in healthy subjects

This study, called a 'Phase I' human pharmacology study, is a very early step in developing a new medicine, CHF6795. Think of it like a meticulous test drive of a new car engine before it's put into a car and driven on the road. The main purpose here isn't to treat an illness, but to understand exactly how the potential new medicine, CHF6795, works in the body and how it might interact with other common medications people might take. The researchers want to see if CHF6795 changes how quickly or slowly other drugs like midazolam (sometimes used for sleep or anxiety), repaglinide (for diabetes), and rosuvastatin (for high cholesterol) are processed and used by your body. This information is crucial for ensuring that if CHF6795 is eventually approved, it can be prescribed safely alongside other necessary medicines.

Even though CHF6795 is being developed to potentially help people with chronic cough, this specific study does not involve anyone who actually has a cough. Instead, it carefully recruits healthy adult volunteers. This allows researchers to focus purely on how CHF6795 and the other drugs interact without other health conditions making the results harder to understand. By gathering this specific information early on, medical professionals can make sure that future studies involving patients are as safe and effective as possible.

This kind of detailed safety and interaction study is a standard and essential part of developing any new medicine. It helps scientists build a clear picture of how new drugs behave in the human body, providing important knowledge needed before any medicine can be made available to help people with health conditions.